key: cord-0702444-ybhfz6f7
authors: Kosmopoulos, Andrew; Bhatt, Deepak L.; Meglis, Gus; Verma, Raj; Pan, Yi; Quan, Adrian; Teoh, Hwee; Verma, Maya; Jiao, Lixia; Wang, Robert; Juliano, Rebecca A.; Kajil, Mahesh; Kosiborod, Mikhail N.; Bari, Basel; Berih, Abdullahi A.; Aguilar, Mallory; Escano, Antonnette; Leung, Andrew; Coelho, Idelta; Hibino, Makoto; Díaz, Rafael; Mason, R. Preston; Steg, Ph. Gabriel; Simon, Tabassome; Go, Alan S.; Ambrosy, Andrew P.; Choi, Richard; Kushner, Arthur M.; Leiter, Lawrence A.; Al-Omran, Mohammed; Verma, Subodh; Mazer, C. David
title: A Randomized Trial of Icosapent Ethyl in Ambulatory Patients with COVID-19
date: 2021-08-26
journal: iScience
DOI: 10.1016/j.isci.2021.103040
sha: 193a2205a186524420d5b028d0d79716dbb10ed2
doc_id: 702444
cord_uid: ybhfz6f7

The coronavirus disease 2019 (COVID-19) pandemic remains a source of considerable morbidity and mortality throughout the world. Therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited. This randomized open-label trial enrolled 100 ambulatory patients with symptomatic COVID-19 in Toronto, Canada. Results indicate that icosapent ethyl (8g daily for 3 days followed by 4g daily for 11 days) significantly reduced high-sensitivity C-reactive protein (hs-CRP) and improved symptomatology compared with patients assigned to usual care. Specifically, the primary biomarker endpoint, change in hs-CRP, was significantly reduced by 25% among treated patients (-0.5mg/L, IQR[-6.9,0.4], within-group P=0.011). Conversely, a non-significant 5.6% reduction was observed among usual care patients (-0.1mg/L, IQR[-3.2,1.7], within-group P=0.51). An unadjusted between-group primary biomarker analysis was non-significant (P=0.082). Overall, this report provides evidence of an early anti-inflammatory effect of icosapent ethyl in a modest sample, including an initial well-tolerated loading dose, in symptomatic COVID-19 outpatients. ClinicalTrials.gov Identifier: NCT04412018.

The coronavirus disease 2019 pandemic remains a source of considerable morbidity and mortality throughout the world, with few safe and effective treatments currently available. Furthermore, the therapies that have demonstrated efficacy (e.g., corticosteroids) studied hospitalized and/or markedly ill patients (Horby et al., 2021) . For the majority of patients in the community who develop symptomatic COVID-19, therapeutic options to reduce symptoms, inflammatory response, or disease progression are limited.

Icosapent ethyl (IPE) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) that is available by prescription in the United States and Canada. In the recently completed REDUCE-IT trial, IPE (administered at an oral dose of 4g daily) reduced major adverse cardiovascular events by 25% in people with or at risk of cardiovascular disease, in a median follow-up period of 4.9 years (Bhatt et al., 2019a) . IPE was also associated with a 20% reduction in cardiovascular death. Further analyses revealed that IPE also reduced recurrent ischemic events, including the need for first and subsequent revascularization procedures (Bhatt et al., 2019b; Peterson et al., 2021) .

Mechanistically, IPE is believed to afford potent vasculoprotective effects (Mason et al., 2020) . Several in vitro and in vivo studies have suggested that EPA improves endothelial function, limits vascular inflammation and reactive oxygen species production, reduces vascular thrombosis, and impedes multiple processes involved in aberrant vascular repair/remodeling (Budoff et al., 2020; Mason et al., 2020; Wang et al., 2020) . Accumulating data also point toward a potent anti-inflammatory effect of EPA, mediated in part through the synthesis of specialized pro-resolving mediators J o u r n a l P r e -p r o o f (Bhatt et al., 2020a; Serhan and Levy, 2018) . These mediators are powerful modulators of the innate and adaptive immune system, implicated in overall resolution of inflammation through effects on host defense, neutrophil trafficking, and cytokine/chemokine elaboration. EPA has been shown to have bactericidal properties and also to limit viral replication and specifically, protectin D1 (PD1), a lipid mediator derived from docosahexaenoic acid (DHA), markedly reduced influenza A virus replication and decreased lethal influenza events in mice (Bhatt et al., 2020b; Morita et al., 2013) . EPA also assists to reduce systemic circulating markers of inflammation in humans (including high-sensitivity C-reactive protein [hs-CRP] and interleukin-6, among others) with most of the evidence coming from patients with hypertriglyceridemia, and increased circulating anti-inflammatory and pro-resolving lipid mediators (Lamon-Fava et al., 2021; Mason, 2019; Muhammad et al., 2011) .

Several lines of evidence implicate endothelial dysfunction as a critical mediator and/or transducer of COVID-19-related pathobiology (Perico et al., 2021; Teuwen et al., 2020) . It is currently believed that SARS-CoV-2 binds endothelial ACE2 to promote widespread endothelialitis, characterized by heightened endothelial-immune interactions and thrombo-inflammation.

Clinically, omega-3 fatty acid use was explored as an agent against COVID-19 in a recent trial by Doaei, et al. (2021) , evaluating a 1000 mg daily concoction (comprised of 400 mg EPA, 200 mg DHA) over a two-week follow-up period. The authors found a significant increase in one-month survival rate, improved kidney function and effects on certain arterial blood gas parameters, favoring treatment over control groups (Doaei et al., 2021) .

Given the aforementioned clinical and biological effects of marine omega-3 fatty acids, we hypothesized that IPE may serve as a potential therapy to reduce inflammation and improve symptoms in patients with COVID-19 (Regidor et al., 2020) .

We herein report the primary results of the open-label, randomized VASCEPA-COVID-19 CardioLink-9 trial of IPE compared with usual care in ambulatory patients with COVID-19 (ClinicalTrials.gov Identifier: NCT04412018) .

With ethical committee approval and informed consent, patients within the Greater Toronto Area, Canada were recruited if they received a positive local SARS-CoV-2 polymerase chain reaction (PCR) test result within the preceding 72 hours of enrollment and at least one of the following symptoms: fever, cough, sore throat, shortness of breath or myalgia. Individuals were excluded if they were hospitalized, pregnant, had a history of acute (<1 month) end-organ injury (e.g., myocardial infarction, stroke, hospitalization for acute lung, liver, or kidney disease), history of acute or chronic pancreatitis, active severe liver disease, hypersensitive to fish, shellfish, or ingredients of IPE, history of hemodynamic instability within the past 72 hours or other situations that reduced the likelihood of completing the study protocol. There was no requirement for having hypertriglyceridemia at entry.

Among 126 individuals assessed for eligibility, 79.4% (n=100) were randomized in a 1:1 ratio to either IPE (a loading dose of 4g twice daily taken orally for 3 days, followed by 2g twice daily for 11 days) or usual care (see STAR METHODS and Figure   J o u r n a l P r e -p r o o f 1). Enrollment began on June 4, 2020, with 14+3-day follow-up through November 6, 2020. Baseline characteristics were similar between groups, and all patients were symptomatic, with myalgia, cough, and loss of taste/smell being amongst the most common symptoms (Figure 2 and Table S1 ).

Analyses hs-CRP level is hypothesized to assist in predicting COVID-19-induced respiratory decline (Mueller et al., 2020) . The prespecified primary biomarker outcome was unadjusted change in hs-CRP from baseline (day 1) to follow-up (day 14+3).

Median between-group baseline levels of hs-CRP were not statistically different (IPE group, 3.2mg/L [interquartile range, IQR 0.9, 11.6]; usual care group, 2.3mg/L [IQR 0.7, 6.5], P=0.16). Among patients randomized to receive IPE, the primary biomarker endpoint of median hs-CRP change at follow-up was -0.5mg/L (IQR [-6.9, 0.4], P=0.011) which corresponds to a 25% significant reduction from baseline levels ( Table   1 ). Among those assigned to receive usual care, median hs-CRP change at follow-up was -0.1mg/L (IQR [-3.2, 1.7], P=0.51). However, a non-significant P-value of 0.082 was obtained when comparing the two groups for unadjusted values. In a post hoc analysis, the between-group difference was significant (P=0.043) after adjustment for age, sex and baseline predicted cardiovascular risk ( Table 1) (Table S2 ). Secondary laboratory parameters are shown in Table S3 .

The prespecified primary clinical outcome for the trial was the change in symptomatology as assessed by the InFLUenza Patient-Reported Outcome (FLU-PRO) score, a validated patient-reported outcome measure used to evaluate the presence, severity and duration of flu-like symptoms in clinical trials Powers 3 rd et al., 2018) . The 32-item FLU-PRO score provides a comprehensive evaluation of the full range of symptoms across six symptom domains including nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic, and the questionnaire was adapted to also capture COVID-19-specific symptoms such as loss of taste/smell.

Patients were asked to rate each FLU-PRO domain on a 5-point ordinal scale that ranged from 0 (no symptoms) to 4 (very frequent symptoms), and to answer COVID-19specific questions with yes/no (see STAR METHODS).

By design, at entry, the prevalence of ≥1 FLU-PRO symptom was 100% in both groups ( Figure 3A ). At 14+3-day follow-up, total symptom prevalence was reduced by 52% in the IPE group (P<0.0001) and by 24% within the usual care group (P=0.0002).

The reductions in symptom prevalence were significant between groups (P=0.005). At baseline, 100% of patients had body/systemic symptoms, the prevalence of which was markedly attenuated in those allocated to IPE versus usual care (P=0.006) ( Figure 3A ). (Table S4) .

Treatment with IPE was well tolerated with a low rate of adverse events overall and a small numeric excess of gastrointestinal side effects (Table S5) .

In summary, we report possible evidence of an early anti-inflammatory effect of IPE, including an initial loading dose, in symptomatic COVID-19 outpatients. The J o u r n a l P r e -p r o o f 8 loading dose was well tolerated with no discontinuations in this first human use of an 8g per day initiation regimen of IPE. While the difference in change in hs-CRP between groups was not statistically significant, changes in inflammatory biomarker levels were associated with a significant improvement in patient-reported symptoms over a 14+3day period. As we await additional larger studies of IPE in the prevention and treatment suggest that IPE may support a safe, well-tolerated, and relatively inexpensive option to manage COVID-19-related symptomatology in the outpatient setting.

Limitations of the study include the modest sample size and open-label design.

The trial was not powered for clinical events such as hospitalization or disease progression. Furthermore, the trial only enrolled ambulatory patients and thus commentary on the potential efficacy of IPE use in more advanced, hospitalized patients or its potential role in the prevention of COVID-19 infection is not possible.

Moreover, the usage of post hoc statistical analyses is a limitation, based on the potential risk of acquiring false positive results.

This was an investigator-initiated trial, supported by grants from Amarin Pharma Inc. 

A schematic outlining the number of individuals who were assessed for eligibility, randomized and included in the analyses. 13 people declined to participate.

Approximately 79% of individuals assessed for eligibility consented to participate and were subsequently randomized. Of the 50 individuals randomized to each group, data from 12% (n=6) of the IPE group and 6% (n=3) of the usual care group were not analyzed for the primary biomarker endpoint based on the lack of paired biomarker data.

J o u r n a l P r e -p r o o f COVID-19 symptoms within 72 hours preceding the baseline visit. Although the IPE group was slightly more symptomatic, the entire study population presented with a large number of baseline symptoms. Almost all patients (98% and 94% in the IPE group and usual care group, respectively) had myalgia. Over half of individuals in both groups had the presence of a cough. Within the IPE arm, 50±2% of patients experienced loss of taste, loss of smell or a fever. These symptoms were present in approximately one-third of the usual care arm. The remaining categories (sore throat and shortness of breath) displayed not more than a 40% prevalence in either group. All between-group comparisons were non-significant. Data shown are for the intention-to-treat population.

The prevalence of FLU-PRO and COVID-19-specific (loss of taste, loss of smell) 

Within-group comparisons of hs-CRP levels for the IPE and usual care cohorts. A significant relative reduction of 25% was observed in hs-CRP level (median change J o u r n a l P r e -p r o o f from baseline of -0.5, P=0.011) in the IPE cohort while there were no significant changes in the usual care cohort (median change from baseline of -0.1, P=0.51). The between-group difference was not significant for the unadjusted values (P=0.082 for change from baseline hs-CRP), but after post hoc adjustment for age, sex, and baseline cardiovascular risk, the between-group P-value was significant (P=0.043 for change from baseline hs-CRP). Sex and age adjustments: men <45 versus ≥45 years and women <55 versus ≥55 years. Adjustments were warranted based on current literature, and occurred post hoc (see STAR METHODS section) (O'Driscoll et al., 2020) . Baseline cardiovascular risk is described as the absence or presence of cardiovascular comorbidities. hs-CRP, high-sensitivity C-reactive protein; IQR, interquartile range. 

The (Table S6) .

Eligible patients were randomly allocated to the IPE group or the usual care group. Randomization was performed using envelope randomization via stratification using random permuted blocks. Patients allocated to the IPE group received a loading dose of 4g IPE twice daily for 3 days followed by 2g twice daily for 11 days. The usual care group received no intervention. Patient characteristics (Table S1 ) were obtained at baseline, while blood samples and clinical outcomes were obtained/measured at baseline and at follow-up. All biological samples were sent to a local certified laboratory for processing.

Although a total of 100 patients were enrolled in the trial, depending on the availability of the data collected, some analyses included less than 50 individuals per group. For instance, biomarker data were not available for some individuals who had available clinical data. Specifically, Table 1 and Tables S2-S4 included 44 and 47 patients in the IPE and usual care cohorts, respectively, which removed patients that did not have paired biomarker data and those who were non-compliant to the treatment. Figure 3A /B included 46 and 49 patients in the IPE and usual care cohorts, respectively, which removed patients that did not have paired FLU-PRO data and those who were noncompliant to the treatment. Figure 2 and Tables S1, S5 and S6 included the intention-to-parameters, unless otherwise specified within the figure/table or figure/table legend.

Baseline characteristics, biomarker, and clinical endpoints were described as frequencies and percentages (for categorical data) or medians with interquartile ranges (for continuous variables). Cohort comparisons were performed with the Wilcoxon Signed Rank (within-group), Mann-Whitney U (between-group, continuous variables) or Spearman correlation coefficient. A P-value of less than 0.05 was considered significant without multiplicity adjustment and all analyses were conducted using a modified intention-to-treat model. The type of statistical tests used to conduct within-and between-group comparisons were determined post hoc. All statistical analyses were conducted using SAS ® software, version 9.4 (Cary, North Carolina).

The VASCEPA-COVID-19 CardioLink-9 Trial has been registered on ClinicalTrials.gov (Identifier: NCT04412018, URL: https://clinicaltrials.gov/ct2/show/NCT04412018).

The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease)

Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Takeda. H.T. reports receiving personal fees from HLS Therapeutics for work conducted outside of the scope of the submitted work

Novo Nordisk, Sanofi, Vifor Pharma

has received a research grant from AMARIN for the PREPARE-IT trial. R.P.M. reports grants and consulting fees from Amgen

Grant support, lecture fees

fees for board membership from Bristol-Myers Squibb, consulting fees and fees for board membership from Sanofi, consulting fees and lecture fees from

has received research grant funding through his institution from Amarin Pharma

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

A Revolution in Omega-3 Fatty Acid Research

Beyond cardiovascular medicine: potential future uses of icosapent ethyl

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial

The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial

Using the Influenza Patient-reported Outcome (FLU-PRO)

Dexamethasone in Hospitalized Patients with Covid-19

Doseand time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation

New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease

Emerging Mechanisms of

Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza

Treatment with w-3 fatty acids reduces serum C-reactive protein concentration

Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients

Age-specific mortality and immunity patterns of SARS-CoV-2

Reduction in Revascularization with Icosapent Ethyl: Insights from REDUCE-IT REVASC

Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO © ) Scores in Influenza-Positive Patients

Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19

Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators